RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3-β pathway

References

• Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: an Overview of Current Therapeutic Strategies. Brain Sci. 2018;8(1):15. doi:10.3390/brainsci8010015.
   PubMed Web of Science ®Google Scholar
• Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg. 2016;124(4):977–13. doi:10.3171/2015.5.JNS142087.
   PubMed Web of Science ®Google Scholar
• Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299–312. doi:10.3322/caac.21613.
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210. doi:10.1016/j.gendis.2016.04.007.
   PubMed Web of Science ®Google Scholar
• Mouly L, Gilhodes J, Lemarié A, Cohen-Jonathan Moyal E, Toulas C, Favre G, Sordet O, Monferran S. The RND1 Small GTPase: main functions and emerging role in Oncogenesis. Int J Mol Sci. 2019;20(15):3612. doi:10.3390/ijms20153612.
   PubMed Web of Science ®Google Scholar
• Chardin P. Function and regulation of Rnd proteins. Nature reviews Molecular cell biology. Nat Rev Mol Cell Biol. 2006;7(1):54–62. doi:10.1038/nrm1788.
   PubMed Web of Science ®Google Scholar
• Basbous S, Azzarelli R, Pacary E, Moreau V. Pathophysiological functions of rnd proteins. Small GTPases. 2021;12(5–6):336–357. doi:10.1080/21541248.2020.1829914.
   PubMedGoogle Scholar
• Xu Y, Sun Q, Yuan F, Dong H, Zhang H, Geng R, Qi Y, Xiong X, Chen Q, Liu B. RND2 attenuates apoptosis and autophagy in glioblastoma cells by targeting the p38 MAPK signalling pathway. J Exp Clin Cancer Res. 2020;39(1):174. doi:10.1186/s13046-020-01671-2.
   PubMed Web of Science ®Google Scholar
• Sun Q, Dong H, Li Y, Yuan F, Xu Y, Mao S, Xiong X, Chen Q, Liu B. Small GTPase RHOE/RND3, a new critical regulator of NF-κB signalling in glioblastoma multiforme? Cell Prolif. 2019;52(5):e12665. doi:10.1111/cpr.12665.
   PubMed Web of Science ®Google Scholar
• Boyrie S, Delmas C, Lemarié A, Lubrano V, Dahan P, Malric L, Luis J, Gilhodes J, Tosolini M, Mouly L, et al. RND1 regulates migration of human glioblastoma stem-like cells according to their anatomical localization and defines a prognostic signature in glioblastoma. Oncotarget. 2018;9(73):33788–33803. doi:10.18632/oncotarget.26082.
   PubMedGoogle Scholar
• Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, et al. The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining ras-MAPK signalling. Nat Cell Biol. 2015;17(1):81–94. doi:10.1038/ncb3082.
   PubMed Web of Science ®Google Scholar
• Qin CD, Ma DN, Zhang SZ, Zhang N, Ren ZG, Zhu XD, Jia QA, Chai ZT, Wang CH, Sun HC, et al. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. Cell Death Disease. 2018;9(5):486. doi:10.1038/s41419-018-0517-x.
   PubMedGoogle Scholar
• Zhao J, Yang S, Cui X, Wang Q, Yang E, Tong F, Hong B, Xiao M, Xin L, Xu C, et al. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma. Neuro Oncol. 2023;25(5):857–870. doi:10.1093/neuonc/noac242.
   PubMed Web of Science ®Google Scholar
• Kinslow CJ, Rae AI, Taparra K, Kumar P, Siegelin MD, Grinband J, Gill BJA, McKhann GM, Sisti MB, Bruce JN, et al. MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas. Clin Cancer Res. 2023;29(21):4399–4407. doi:10.1158/1078-0432.CCR-23-1295.
   PubMed Web of Science ®Google Scholar
• Maugeri G, D’Amico AG, Saccone S, Federico C, Rasà DM, Caltabiano R, Broggi G, Giunta S, Musumeci G, D’Agata V. Effect of PACAP on hypoxia-induced angiogenesis and epithelial–mesenchymal transition in Glioblastoma. Biomedicines. 2021;9(8):965. doi:10.3390/biomedicines9080965.
   PubMed Web of Science ®Google Scholar
• D’Amico AG, Maugeri G, Vanella L, Pittalà V, Reglodi D, D’Agata V. Multimodal Role of PACAP in Glioblastoma. Brain Sci. 2021;11(8):994. doi:10.3390/brainsci11080994.
   PubMed Web of Science ®Google Scholar
• Tomar VS, Patil V, Somasundaram K. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020;36(3):273–278. doi:10.1007/s10565-019-09502-7.
   PubMed Web of Science ®Google Scholar
• Tang Q, Cao H, Tong N, Liu Y, Wang W, Zou Y, Xu L, Zeng Z, Xu W, Yin Z, et al. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine. 2022;99:154016. doi:10.1016/j.phymed.2022.154016.
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. nature reviews clinical oncology. Nat Rev Clin Oncol. 2017;14(10):611–629. doi:10.1038/nrclinonc.2017.44.
   PubMed Web of Science ®Google Scholar
• Sun Q, Xu Y, Yuan F, Qi Y, Wang Y, Chen Q, Liu B. Rho family GTPase 1 (RND1), a novel regulator of p53, enhances ferroptosis in glioblastoma. Cell & Bioscience. 2022;12(1):53. doi:10.1186/s13578-022-00791-w.
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110. doi:10.1038/nrc3447.
   PubMed Web of Science ®Google Scholar
• Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647. doi:10.15252/embj.2021108647.
   PubMed Web of Science ®Google Scholar
• Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res. 2019;79(6):1019–1031. doi:10.1158/0008-5472.CAN-18-2738.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhao S, Yu W, Rao T, Ruan Y, Zhu S, Xia Y, Song H, Cheng F. SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/β-catenin pathway. J Cell Mol Med. 2021;25(22):10684–10697. doi:10.1111/jcmm.17005.
   PubMed Web of Science ®Google Scholar
• Wen L, Wang K, Zhang F, Tan Y, Shang X, Zhu Y, Zhou X, Yuan H, Hu F. AKT activation by SC79 to transiently re-open pathological blood brain barrier for improved functionalized nanoparticles therapy of glioblastoma. Biomaterials. 2020;237:119793. doi:10.1016/j.biomaterials.2020.119793.
   PubMed Web of Science ®Google Scholar
• Anjum K, Shagufta BI, Abbas SQ, Patel S, Khan I, Shah SAA, Akhter N, Hassan SSU. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. Biomed Pharmacother Biomed Pharmacotherapie. 2017;92:681–689. doi:10.1016/j.biopha.2017.05.125.
   PubMed Web of Science ®Google Scholar
• de Souza LE, Moura Costa MD, Bilek ES, Lopes MH, Martins VR, Püschel AW, Mercadante AF, Nakao LS, Zanata SM, de Souza LER. STI1 antagonizes cytoskeleton collapse mediated by small GTPase Rnd1 and regulates neurite growth. Exp Cell Res. 2014;324(1):84–91. doi:10.1016/j.yexcr.2014.03.017.
   PubMed Web of Science ®Google Scholar
• Li YH, Ghavampur S, Bondallaz P, Will L, Grenningloh G, Pu Schel AW. Rnd1 regulates axon extension by enhancing the microtubule destabilizing activity of SCG10. J Biol Chem. 2009;284(1):363–371. doi:10.1074/jbc.M808126200.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Katoh H, Negishi M. Small GTPase Rnd1 is involved in neuronal activity-dependent dendritic development in hippocampal neurons. Neurosci Lett. 2006;400(3):218–223. doi:10.1016/j.neulet.2006.02.064.
   PubMed Web of Science ®Google Scholar
• Komatsu H, Iguchi T, Masuda T, Hirata H, Ueda M, Kidogami S, Ogawa Y, Sato K, Hu Q, Nambara S, et al. Attenuated RND1 expression confers malignant phenotype and predicts poor prognosis in hepatocellular carcinoma. annals of surgical oncology. Ann Surg Oncol. 2017;24(3):850–859. doi:10.1245/s10434-016-5573-9.
   PubMed Web of Science ®Google Scholar
• Gao L, Liu J, Xu P, Deng G, Liu B, Yuan F, Tan Y, Sun Q, Xu Y, Zhang H, et al. AKT inhibitor SC66 inhibits proliferation and induces apoptosis in human glioblastoma through down-regulating AKT/β-catenin pathway. Front Pharmacol. 2020;11:1102. doi:10.3389/fphar.2020.01102.
   PubMed Web of Science ®Google Scholar
• Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22):33440–33450. doi:10.18632/oncotarget.7961.
   PubMedGoogle Scholar
• Westhoff MA, Karpel-Massler G, Brühl O, Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L, Debatin KM. A critical evaluation of PI3K inhibition in Glioblastoma and neuroblastoma therapy. Mol Cell Ther. 2014;2(1):32. doi:10.1186/2052-8426-2-32.
   PubMedGoogle Scholar
• Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J. MGMT Status as a Clinical Biomarker in Glioblastoma. Trends Cancer. 2020;6(5):380–391. doi:10.1016/j.trecan.2020.02.010.
   PubMed Web of Science ®Google Scholar
• Wang X, Jia L, Jin X, Liu Q, Cao W, Gao X, Yang M, Sun B. NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells. Oncol Lett. 2015;9(6):2586–2590. doi:10.3892/ol.2015.3130.
   PubMed Web of Science ®Google Scholar
• Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H, Tanaka S. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther. 2012;11(6):1289–1299. doi:10.1158/1535-7163.MCT-11-0801.
   PubMed Web of Science ®Google Scholar
• Ueno H, Tomiyama A, Yamaguchi H, Uekita T, Shirakihara T, Nakashima K, Otani N, Wada K, Sakai R, Arai H, et al. Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-jun terminal kinase-paxillin axis. Biochem Bioph Res Co. 2015;468(1–2):240–247. doi:10.1016/j.bbrc.2015.10.122.
   PubMed Web of Science ®Google Scholar
• Montaldi AP, Godoy PR, Sakamoto-Hojo ET. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Mutat Res Genet Toxicol Environ Mutagen. 2015;793:19–29. doi:10.1016/j.mrgentox.2015.06.001.
   PubMed Web of Science ®Google Scholar
• Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I, et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 2010;296(2):241–248. doi:10.1016/j.canlet.2010.04.013.
   PubMed Web of Science ®Google Scholar
• Dai S, Yan Y, Xu Z, Zeng S, Qian L, Huo L, Li X, Sun L, Gong Z. SCD1 confers temozolomide resistance to human glioma cells via the Akt/GSK3β/β-catenin signaling axis. Front Pharmacol. 2017;8:960. doi:10.3389/fphar.2017.00960.
   PubMed Web of Science ®Google Scholar
• Liu W, Jing ZT, Wu SX, He Y, Lin YT, Chen WN, Lin XJ, Lin X. A novel AKT activator, SC79, prevents acute hepatic failure induced by fas-mediated apoptosis of hepatocytes. Am J Pathol. 2018;188(5):1171–1182. doi:10.1016/j.ajpath.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer. 2023;9(1):9–27. doi:10.1016/j.trecan.2022.09.005.
   PubMed Web of Science ®Google Scholar
• Nam Y, Koo H, Yang Y, Shin S, Zhu Z, Kim D, Cho HJ, Mu Q, Choi SW, Sa JK, et al. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. Genome Med. 2023;15(1):16. doi:10.1186/s13073-023-01165-8.
   PubMed Web of Science ®Google Scholar
• Tatari N, Khan S, Livingstone J, Zhai K, McKenna D, Ignatchenko V, Chokshi C, Gwynne WD, Singh M, Revill S, et al. The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers. Acta Neuropathol. 2022;144(6):1127–1142. doi:10.1007/s00401-022-02506-4.
   PubMed Web of Science ®Google Scholar
• Romeo G, Ciaffaglione V, Amata E, Dichiara M, Calabrese L, Vanella L, Sorrenti V, Grosso S, D’Amico AG, D’Agata V, et al. Combination of Heme Oxygenase-1 Inhibition and Sigma Receptor Modulation for Anticancer Activity. Molecules. 2021;26(13):3860. doi:10.3390/molecules26133860.
   PubMed Web of Science ®Google Scholar
• Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res. 2022;41(1):35. doi:10.1186/s13046-022-02251-2.
   PubMed Web of Science ®Google Scholar